CLINICAL TRIALS PROFILE FOR PENICILLIN G POTASSIUM

All Clinical Trials for PENICILLIN G POTASSIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00288769 ↗	Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis	Completed	Soroka University Medical Center	N/A	2006-03-01	Background: Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids . Methods: A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets. Purpose of the research: To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS). Study hypothesis: Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.
NCT00317629 ↗	Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Terminated	Secretaria de Salud de Santander	Phase 3	2006-05-01	Cutaneous leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis. A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be administered daily and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In the case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.
NCT00317629 ↗	Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Terminated	Secretaria de Salud de Tolima	Phase 3	2006-05-01	Cutaneous leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis. A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be administered daily and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In the case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.
NCT00317629 ↗	Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Terminated	The University of Akron	Phase 3	2006-05-01	Cutaneous leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis. A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be administered daily and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In the case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.
NCT00317629 ↗	Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Terminated	Universidad de Antioquia	Phase 3	2006-05-01	Cutaneous leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis. A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be administered daily and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In the case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.

Clinical Trial Conditions for PENICILLIN G POTASSIUM

Condition Name

Condition Name for PENICILLIN G POTASSIUM
Intervention	Trials
Cutaneous Leishmaniasis	1
Metastatic Cancer	1
Recurrent Aphthous Stomatitis	1
Sepsis	1

Condition MeSH

Condition MeSH for PENICILLIN G POTASSIUM
Intervention	Trials
Sepsis	1
Leishmaniasis, Cutaneous	1
Leishmaniasis	1
Stomatitis, Aphthous	1

Clinical Trial Locations for PENICILLIN G POTASSIUM

Trials by Country

Trials by Country for PENICILLIN G POTASSIUM
Location	Trials
United States	1
Colombia	1
Israel	1
China	1

Trials by US State

Trials by US State for PENICILLIN G POTASSIUM
Location	Trials
New York	1

Clinical Trial Progress for PENICILLIN G POTASSIUM

Clinical Trial Phase

Clinical Trial Phase for PENICILLIN G POTASSIUM
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for PENICILLIN G POTASSIUM
Clinical Trial Phase	Trials
Withdrawn	1
Completed	1
Terminated	1

Clinical Trial Sponsors for PENICILLIN G POTASSIUM

Sponsor Name

Sponsor Name for PENICILLIN G POTASSIUM
Sponsor	Trials
Universidad de Antioquia	1
Universidad de Santander	1
Fundación Cardiovascular de Colombia	1

Sponsor Type

Sponsor Type for PENICILLIN G POTASSIUM
Sponsor	Trials
Other	10

Penicillin G Potassium Clinical Trials, Market Analysis, Patent Status and 2025-2030 Projection

Last updated: July 30, 2026

Penicillin G potassium, also called benzylpenicillin potassium, is an established injectable penicillin used for serious infections caused by susceptible organisms, including streptococcal disease, meningococcal infections, syphilis, clostridial infections, and selected cases of endocarditis. Its commercial profile is mature: clinical innovation is limited, generic competition is extensive, and demand is driven mainly by hospital procurement, antimicrobial-resistance protocols, public-health programs, and supply reliability.

The product has no meaningful branded exclusivity platform comparable with newer antibiotics. Market growth is likely to remain modest through 2030, with pricing constrained by generic competition. The principal commercial risks are manufacturing interruptions, shortages of sterile injectable products, reduced use caused by resistance or alternative therapies, and procurement substitution among penicillin G formulations.

What is penicillin G potassium and how is it used?

Penicillin G potassium is the potassium salt of benzylpenicillin, a beta-lactam antibiotic administered by intravenous or intramuscular injection. It is rapidly hydrolyzed to active benzylpenicillin after administration and inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins.

The FDA-approved labeling identifies uses that include:

• Serious infections caused by susceptible streptococci.
• Pneumococcal infections.
• Meningococcal disease.
• Syphilis and other treponemal infections.
• Clostridial infections, including gas gangrene.
• Diphtheria, in combination with antitoxin.
• Anthrax caused by susceptible Bacillus anthracis.
• Selected infections caused by susceptible anaerobic organisms.

The potassium formulation is generally used when high systemic concentrations are required and oral therapy is unsuitable. Dosing depends on infection site, organism susceptibility, renal function, and severity. The formulation is distinct from penicillin G benzathine and penicillin G procaine, which have prolonged absorption profiles and different clinical uses. (U.S. Food and Drug Administration [FDA], 2023a)

What is the current clinical-trial status of penicillin G potassium?

Penicillin G potassium has no active development program comparable with a new molecular entity. Its clinical evidence base consists mainly of historical randomized studies, observational studies, pharmacokinetic investigations, antimicrobial-guideline evaluations, and trials in which penicillin G is one treatment arm.

Recent clinical research areas

Research area	Current role of penicillin G potassium	Commercial implication
Syphilis treatment	Benzathine penicillin G remains the standard for most uncomplicated syphilis; aqueous penicillin G is used in neurosyphilis and ocular disease	Stable public-health demand, but potassium salt is a specialized segment
Infective endocarditis	Used selectively for highly susceptible streptococcal infections	Hospital and infectious-disease specialist demand
Streptococcal toxic shock and severe invasive disease	May be used with clindamycin or other agents under guideline-directed treatment	Niche demand linked to severe infections
Meningitis	Use depends on susceptibility and central nervous system penetration requirements	Reduced by broad-spectrum alternatives and resistance concerns
Congenital syphilis	Aqueous crystalline penicillin G is a standard treatment option in neonates	Public-health procurement remains important
Antimicrobial stewardship	Used where narrow-spectrum therapy is clinically appropriate	Supports continued use in hospitals with stewardship programs
Drug shortages and substitutions	Studies and guidance address alternative penicillin products and dosing	Supply continuity is a major purchasing factor

ClinicalTrials.gov lists studies involving penicillin G or benzylpenicillin across infectious-disease indications, but the drug is generally evaluated as an established treatment rather than as a new product candidate. No late-stage trial is expected to create a new period of regulatory exclusivity for penicillin G potassium. (National Library of Medicine, 2024)

What FDA regulatory status applies to penicillin G potassium?

Penicillin G potassium is an established prescription injectable antibiotic. U.S. products are marketed under approved labeling for penicillin G potassium for injection. The products are supplied as sterile powders that are reconstituted before administration.

FDA product characteristics

Attribute	Status
Active ingredient	Penicillin G potassium, benzylpenicillin potassium
Therapeutic class	Natural penicillin antibacterial
Route	Intravenous or intramuscular, depending on product labeling and clinical use
Dosage form	Sterile powder for injection
Regulatory pathway	Established prescription antibiotic products
Pediatric use	Included for labeled indications, with weight- and indication-based dosing
Main safety concerns	Hypersensitivity, anaphylaxis, electrolyte load, neurotoxicity at high concentrations, seizures, and injection-related reactions
Primary substitutes	Penicillin G sodium, penicillin G benzathine, penicillin G procaine, and other beta-lactam antibiotics

The potassium salt carries a potassium burden that can be clinically relevant in patients with renal impairment, hyperkalemia, heart failure, or other conditions in which electrolyte loading is a concern. Penicillin G sodium may be preferred in some patients, although the sodium load of that formulation also requires consideration. (FDA, 2023a; FDA, 2023b)

What is the Orange Book status of penicillin G potassium?

Penicillin G potassium is a mature generic injectable product and does not have a commercially relevant period of new-drug exclusivity. Orange Book treatment is product-specific and depends on the listed manufacturer, dosage form, strength, and approval pathway.

The practical market position is:

1. No active branded franchise protects the molecule.
2. No meaningful market exclusivity is expected for the basic active ingredient.
3. Generic manufacturers can compete through approved injectable products.
4. Product availability depends more on manufacturing capacity and FDA compliance than on patent barriers.
5. Any patent risk is more likely to concern a specific formulation, container, manufacturing process, or delivery system than benzylpenicillin potassium itself.

FDA Orange Book records should be reviewed by National Drug Code and application number because product listings and marketing status can change. The absence of an active patent barrier does not guarantee immediate entry by a new supplier. Sterile manufacturing validation, facility capacity, inspection history, and procurement qualification are material barriers. (FDA, 2024)

What patents protect penicillin G potassium?

The core compound is an old antibiotic discovered and developed in the first half of the 20th century. Compound patents and original use patents have expired. A new entrant would not ordinarily face blocking patent claims covering benzylpenicillin potassium as a conventional injectable active ingredient.

Patent risk by category

Patent category	Risk for standard penicillin G potassium injection	Assessment
Core compound	None	Historical patents expired
Conventional sterile powder formulation	Low	Mature technology with extensive prior art
Standard reconstitution and injection use	Low	Established medical practice
Novel stability formulation	Low to moderate	Depends on claim scope and jurisdiction
Ready-to-use delivery system	Moderate	Device and container claims may apply
Controlled-release formulation	Moderate to high	Relevant mainly to nonstandard products
Manufacturing process	Low to moderate	Process patents may affect specific suppliers
Combination therapy	Low to moderate	Claims may cover a particular regimen or indication
Packaging and container closure	Low to moderate	Commercially relevant where stability is difficult

Patent duration is not the principal barrier to market participation. For standard injectable products, regulatory compliance and supply-chain execution are more important than patent clearance.

When does penicillin G potassium lose exclusivity?

Penicillin G potassium lost meaningful product exclusivity decades ago. The active ingredient is a generic, off-patent antibiotic. No conventional patent-expiration date is likely to alter the competitive landscape between 2025 and 2030.

Market exclusivity can still arise temporarily from:

• A newly approved delivery system.
• A novel ready-to-use formulation.
• A new combination product.
• Orphan-drug designation for a specific product and indication.
• A manufacturer-specific regulatory exclusivity period.

Those mechanisms do not generally apply to standard penicillin G potassium for injection.

Are there Paragraph IV challenges involving penicillin G potassium?

Paragraph IV litigation is unlikely to be commercially significant for conventional penicillin G potassium products. Paragraph IV certifications are most relevant when an abbreviated new drug application references a listed drug with unexpired patents. Because the basic product is old and generic, a new entrant would more likely encounter ordinary ANDA review, manufacturing requirements, and potential product-specific patents than a major patent challenge.

The litigation profile differs from newer antibiotics, where Paragraph IV filings can trigger Hatch-Waxman litigation and a 30-month stay. For penicillin G potassium, the more probable disputes concern:

• Manufacturing quality.
• Sterility failures.
• Labeling or formulation differences.
• Contract supply obligations.
• Product liability.
• Shortage allocation and procurement contracts.

What clinical and commercial factors are driving demand?

Demand is supported by the drug’s narrow spectrum, low acquisition cost, and continuing role in severe infections. It is constrained by the availability of ceftriaxone, ampicillin, amoxicillin, piperacillin-tazobactam, vancomycin, and other agents.

Demand drivers

Hospital systems continue to use penicillin G potassium where susceptibility is documented and narrow-spectrum treatment is preferred. Public-health demand is linked to syphilis, congenital syphilis, neurosyphilis, and invasive streptococcal infections. In resource-limited settings, benzylpenicillin remains important because of its low cost and broad historical clinical experience. WHO classifies benzylpenicillin among essential antibacterial medicines. (World Health Organization, 2023)

Demand constraints

Use can decline when:

• Local resistance patterns favor other beta-lactams.
• Clinicians prefer more convenient dosing.
• Product shortages force substitution.
• Hospitals consolidate procurement around fewer injectable suppliers.
• Potassium or sodium electrolyte concerns affect formulation selection.
• Penicillin allergy labels reduce prescribing.

Global syphilis incidence has increased in several regions, supporting demand for penicillin products, although much of the syphilis market uses benzathine penicillin G rather than penicillin G potassium. The two products should not be treated as interchangeable market segments. (World Health Organization, 2024)

How does penicillin G potassium compare with competing penicillin products?

Product	Main commercial use	Formulation profile	Competitive position
Penicillin G potassium	Severe susceptible infections, neurosyphilis, congenital syphilis, endocarditis	Aqueous, short-acting injectable	Hospital and specialist product
Penicillin G sodium	Similar severe infections	Aqueous, short-acting injectable	Direct formulation substitute
Penicillin G benzathine	Syphilis and selected streptococcal infections	Long-acting intramuscular suspension	Separate high-volume public-health segment
Penicillin G procaine	Selected infections requiring prolonged exposure	Procaine-based injectable	Narrower and declining role
Ampicillin	Enterococcal, Listeria, and other susceptible infections	Injectable and oral products	Broader clinical substitution
Ceftriaxone	Meningitis, gonorrhea, pneumonia, sepsis	Once-daily injectable	Convenience-driven substitute
Piperacillin-tazobactam	Broad-spectrum hospital infections	Injectable	Substitute where broader coverage is needed

Penicillin G potassium competes primarily on spectrum, clinical familiarity, and acquisition cost. It competes poorly on convenience, dosing frequency, and resistance coverage.

How large is the penicillin G potassium market?

Public market datasets usually aggregate penicillin products, natural penicillins, injectable antibiotics, or beta-lactams rather than reporting penicillin G potassium as a standalone global category. Exact revenue estimates therefore vary according to whether they include penicillin G sodium, benzathine penicillin, hospital tender sales, and private-label products.

The standalone market is best characterized as a small, mature injectable-antibiotic segment:

• Low unit-price pressure.
• High volume concentration in hospitals and public procurement.
• Limited branded promotion.
• Strong generic participation.
• Disproportionate exposure to sterile-injectable shortages.
• Low probability of sustained premium pricing without a differentiated formulation.

2025-2030 market projection

Scenario	2025-2030 unit trend	2025-2030 revenue trend	Main assumptions
Base case	Flat to low-single-digit growth	Flat to low-single-digit growth	Stable hospital use, generic pricing, modest infectious-disease demand
Upside case	Low- to mid-single-digit growth	Mid-single-digit growth	Higher syphilis and invasive streptococcal treatment, supply normalization, expanded procurement
Downside case	Low-single-digit decline	Mid-single-digit decline	Substitution by ceftriaxone or other agents, shortages, declining use of aqueous penicillin

A reasonable base-case outlook is a mature market with volume resilience and limited revenue expansion. Growth is more likely to come from additional treatment episodes than from price increases. Manufacturers with reliable sterile production, multiple vial sizes, validated cold-chain or controlled-temperature distribution, and public-sector tender access are better positioned than companies relying on retail demand.

What generic launch risks exist for penicillin G potassium?

A new generic entrant faces low patent risk but meaningful operational risk.

Manufacturing and regulatory barriers

Sterile injectable production requires validated aseptic processing, environmental controls, container-closure integrity, particulate control, sterility testing, and reliable active-ingredient sourcing. FDA warning letters, import alerts, or remediation can remove a supplier from the market even when demand is stable.

Potential launch barriers include:

• Limited availability of qualified penicillin fermentation capacity.
• Cross-contamination controls for beta-lactam production.
• Facility segregation requirements.
• Sterile powder filling capacity.
• Potency and stability testing.
• Hospital formulary qualification.
• Government tender registration.
• Supply guarantees and shortage contingency requirements.

For this product, manufacturing IP is less important than process know-how, inspection readiness, and dependable supply.

Which companies compete in penicillin G potassium?

Competition varies by jurisdiction and procurement channel. The market includes large generic injectable manufacturers, regional sterile-product companies, and suppliers selling through hospital wholesalers or government tenders. Pfizer has historically marketed penicillin G products and remains an important reference company for injectable penicillin products, while generic competition comes from multiple manufacturers depending on country and regulatory approval status.

The relevant competitive variables are:

• FDA or equivalent regulatory approval.
• Current commercial availability.
• Manufacturing-site reliability.
• Annual supply capacity.
• Vial and package configurations.
• Tender pricing.
• Shortage history.
• Distribution reach.
• Ability to supply both potassium and sodium formulations.

Company-level market-share rankings are unreliable without jurisdiction-specific procurement data because hospital contracts and shortage-driven substitutions can materially change quarterly sales.

What is the litigation and settlement outlook?

The drug has low expected patent-litigation exposure. There is no apparent commercial basis for a major branded-generic settlement cycle involving standard penicillin G potassium injection. Litigation risk is more likely to arise from product quality, supply contracts, regulatory enforcement, or adverse events.

The absence of patent litigation does not eliminate commercial disputes. Hospitals and government buyers may pursue remedies for delayed delivery, product recalls, or failure to meet tender quantities.

Key Takeaways

• Penicillin G potassium is an established, off-patent injectable antibiotic.
• No major clinical-development program is expected to create new exclusivity.
• The core compound, conventional injection, and standard uses have no meaningful remaining patent protection.
• Paragraph IV litigation is unlikely to be a material market event.
• Demand is supported by severe susceptible infections, syphilis-related public-health programs, and antimicrobial stewardship.
• The main substitutes are penicillin G sodium, penicillin G benzathine, ceftriaxone, ampicillin, and broader-spectrum hospital antibiotics.
• The 2025-2030 outlook is mature and low-growth, with revenue likely to remain flat to low-single-digit growth in the base case.
• Sterile manufacturing capacity, FDA compliance, procurement access, and shortage management are more important than patent exclusivity.
• Potassium and benzathine formulations represent different clinical and commercial markets and should not be combined in revenue analysis.

FAQs about penicillin G potassium

Is penicillin G potassium the same as benzathine penicillin?

No. Penicillin G potassium is an aqueous, short-acting benzylpenicillin formulation. Benzathine penicillin G is a long-acting intramuscular formulation used extensively for syphilis and other indications requiring prolonged exposure.

Is penicillin G potassium still used for syphilis?

Yes. It is used in specific settings, including neurosyphilis, ocular syphilis, and congenital syphilis. Benzathine penicillin G is generally the principal product for uncomplicated adult syphilis.

Can penicillin G potassium be replaced by penicillin G sodium?

Often, but not automatically. The active penicillin is the same, while the counter-ion and electrolyte burden differ. Selection depends on the patient’s condition, renal function, product labeling, and local supply.

Does penicillin G potassium have biosimilar competition?

No. Biosimilars apply to complex biological products. Penicillin G potassium is a small-molecule antibiotic and competes through generic injectable products.

What is the largest commercial risk for penicillin G potassium manufacturers?

The largest risk is usually supply interruption rather than patent challenge. Sterile manufacturing failures, active-ingredient shortages, facility remediation, and procurement concentration can quickly affect market availability.

References

1. National Library of Medicine. (2024). ClinicalTrials.gov: Search results for benzylpenicillin and penicillin G. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2023a). Penicillin G potassium for injection prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023b). Penicillin G sodium for injection prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.

6. World Health Organization. (2024). Global sexually transmitted infections surveillance and syphilis epidemiology resources. WHO.